Index of /wp-content/uploads/2016/10

 NameLast modifiedSizeDescription
 Parent Directory   -  
 slide_nou_srh_1-100x..>2016-10-04 21:36 2.5K 
 slide_nou_srh_2-100x..>2016-10-04 21:44 2.5K 
 slide_nou_srh_3-100x..>2016-10-04 21:44 3.0K 
 slide_nou_srh_2-150x..>2016-10-04 21:38 4.8K 
 slide_nou_srh_1-150x..>2016-10-04 21:32 5.3K 
 slide_nou_srh_2-180x..>2016-10-04 21:38 6.0K 
 slide_nou_srh_1-180x..>2016-10-04 21:32 6.6K 
 slide_nou_srh_1-300x..>2016-10-04 21:32 8.0K 
 slide_nou_srh_3-150x..>2016-10-04 21:40 8.4K 
 slide_nou_srh_2-300x..>2016-10-04 21:38 8.4K 
 slide_nou_srh_3-180x..>2016-10-04 21:40 11K 
 slide_nou_srh_2-300x..>2016-10-04 21:38 11K 
 slide_nou_srh_3-300x..>2016-10-04 21:40 12K 
 slide_nou_srh_1-300x..>2016-10-04 21:32 13K 
 slide_nou_srh_1-600x..>2016-10-04 21:32 20K 
 slide_nou_srh_2-600x..>2016-10-04 21:38 21K 
 slide_nou_srh_3-300x..>2016-10-04 21:40 24K 
 slide_nou_srh_1-768x..>2016-10-04 21:32 27K 
 slide_nou_srh_2-768x..>2016-10-04 21:38 29K 
 slide_nou_srh_2-600x..>2016-10-04 21:38 30K 
 slide_nou_srh_1-600x..>2016-10-04 21:32 31K 
 slide_nou_srh_3-600x..>2016-10-04 21:40 35K 
 slide_nou_srh_1-1024..>2016-10-04 21:32 40K 
 slide_nou_srh_2-1024..>2016-10-04 21:38 44K 
 slide_nou_srh_3-768x..>2016-10-04 21:40 51K 
 slide_nou_srh_3-600x..>2016-10-04 21:40 68K 
 slide_nou_srh_3-1024..>2016-10-04 21:40 80K 
 Autologous-Stem-Cell..>2016-10-04 20:48 121K 
 slide_nou_srh_2.jpg 2016-10-04 21:38 137K 
 The-Outcome-of-Autol..>2016-10-04 20:37 147K 
 Anticoagulant-Relate..>2016-10-04 20:49 161K 
 CNS-Lymphomas-News-i..>2016-10-04 20:46 179K 
 P11-Aspects-Regardin..>2016-10-04 18:59 180K 
 Eligibility-Criteria..>2016-10-04 20:45 195K 
 The-Management-of-Ha..>2016-10-04 20:37 203K 
 Solitary-Plasmaytoma..>2016-10-04 20:40 244K 
 The-porphyrias-part-..>2016-10-01 11:24 247K 
 Serological-Screenin..>2016-10-04 20:40 248K 
 The-Differential-Dia..>2016-10-04 19:00 249K 
 Clinical-and-Biologi..>2016-10-04 20:46 255K 
 Pathogenetic-and-The..>2016-10-04 20:40 256K 
 Hemolytic-Disease-of..>2016-10-04 20:43 257K 
 Updates-in-Immunolog..>2016-10-04 20:38 268K 
 Incidence-and-Clinic..>2016-10-04 20:43 275K 
 First-Two-Years-Expe..>2016-10-04 20:44 277K 
 Splenic-Marginal-Zon..>2016-10-04 20:39 283K 
 Haploidentical-Stem-..>2016-10-04 20:43 283K 
 Hemolysis-Quality-Co..>2016-10-04 20:43 287K 
 Low-Variants-Rh-Stud..>2016-10-04 20:42 294K 
 slide_nou_srh_3.jpg 2016-10-04 21:40 301K 
 Transfusion-Therapy-..>2016-10-04 20:38 305K 
 New-Treatment-Option..>2016-10-04 20:41 308K 
 The-Importance-of-Cl..>2016-10-04 20:37 309K 
 Global-Burden-and-Tr..>2016-10-04 20:44 311K 
 Multiple-Myeloma-in-..>2016-10-04 20:42 317K 
 Haplo-Identical-Bone..>2016-10-01 11:24 323K 
 Cardiovascular-Compl..>2016-10-04 20:47 325K 
 Specific-Features-of..>2016-10-04 20:39 327K 
 Searching-for-an-Unr..>2016-10-04 20:39 329K 
 Monitoring-Patients-..>2016-10-04 20:42 329K 
 Pharmacological-Stud..>2016-10-04 20:41 335K 
 Hematophobia-Crystal..>2016-10-04 20:44 341K 
 Update-in-Immune-Thr..>2016-10-04 20:38 341K 
 Evaluation-of-the-Si..>2016-10-04 20:44 355K 
 Central-Venous-Cathe..>2016-10-04 20:47 357K 
 Diagnostic-Problems-..>2016-10-04 20:45 367K 
 Extreme-Thrombocytos..>2016-10-04 20:45 367K 
 The-Monoclonal-Gammo..>2016-10-04 20:37 369K 
 Different-Therapeuth..>2016-10-04 20:45 373K 
 Clinical-Case-of-Apl..>2016-10-04 20:47 381K 
 PET-CT-in-Assessemen..>2016-10-04 20:41 382K 
 The-First-18-Months-..>2016-10-04 20:38 383K 
 Acute-Myeloid-Leukem..>2016-10-04 20:48 385K 
 Integrated-Approach-..>2016-10-04 20:43 386K 
 Clinico-Pathological..>2016-10-04 20:47 388K 
 Caelyx-Therapy-in-Re..>2016-10-04 20:47 392K 
 Retrospective-Analys..>2016-10-04 20:40 393K 
 Gold-Nanoparticles-C..>2016-10-04 20:44 395K 
 Incidence-and-Clinic..>2016-10-04 20:43 396K 
 Paroxistic-Nocturnal..>2016-10-04 20:40 405K 
 Hiperferritinemia-in..>2016-10-04 20:43 406K 
 Complications-of-Che..>2016-10-04 20:46 407K 
 Autoimmune-Hemolytic..>2016-10-04 20:49 409K 
 The-Management-of-Ac..>2016-10-04 20:37 410K 
 The-Value-of-a-High-..>2016-10-04 20:36 415K 
 Current-Concepts-of-..>2016-10-04 20:46 421K 
 The-national-program..>2016-10-01 11:24 436K 
 JAK-Inhibitor-Therap..>2016-10-04 20:42 438K 
 Therapeutic-Results-..>2016-10-04 20:38 441K 
 A-Case-of-Acute-Lymp..>2016-10-04 20:48 443K 
 New-Born-Hemolytic-D..>2016-10-04 20:41 450K 
 The-Experience-of-a-..>2016-10-04 18:59 450K 
 Allogeneic-and-Autol..>2016-10-04 20:48 451K 
 The-Results-of-Treat..>2016-10-04 20:37 454K 
 Chronic-Immune-Throm..>2016-10-04 20:47 461K 
 CTS-UTS-Importance-o..>2016-10-04 20:46 462K 
 Occult-Hepatitis-B-I..>2016-10-04 20:41 472K 
 Transfusion-Therapeu..>2016-10-04 20:39 489K 
 Management-of-a-Refr..>2016-10-04 20:42 493K 
 West-Nile-Virus-Infe..>2016-10-04 20:38 496K 
 The-Treatment-with-5..>2016-10-04 20:36 497K 
 Rare-Association-Bet..>2016-10-04 20:40 498K 
 Viral-Infections-aft..>2016-10-04 20:38 503K 
 Challenges-in-Implem..>2016-10-04 20:47 507K 
 Recent-Advances-in-D..>2016-10-04 20:40 510K 
 The-Result-of-Molecu..>2016-10-04 20:37 511K 
 Acute-Myeloid-Leukem..>2016-10-04 20:48 511K 
 Diagnosis-by-Immunop..>2016-10-04 20:45 524K 
 BLC-2-Expression-as-..>2016-10-04 20:48 535K 
 Evolutions-of-Preval..>2016-10-04 20:45 539K 
 Chronic-Myeloid-Leuk..>2016-10-04 20:46 542K 
 Evaluating-the-Effic..>2016-10-04 20:44 549K 
 Impact-of-Nonspecifi..>2016-10-04 20:42 549K 
 Updates-in-acquired-..>2016-10-01 11:24 550K 
 The-Impact-of-Molecu..>2016-10-04 20:37 553K 
 Primary-Cutaneous-Ly..>2016-10-04 20:41 559K 
 Transformation-Modal..>2016-10-04 20:38 566K 
 Estimation-of-Residu..>2016-10-04 20:45 569K 
 Communication-Strate..>2016-10-04 20:46 570K 
 Gold-Nanoparticle-Bi..>2016-10-04 20:44 574K 
 Stem-Cell-Transplant..>2016-10-04 20:39 591K 
 Study-of-Membrane-Fl..>2016-10-04 20:39 612K 
 slide_nou_srh_1.jpg 2016-10-04 21:32 612K 
 Secondary-Acute-Myel..>2016-10-04 20:39 616K 
 The-Chemotherapy-Tre..>2016-10-04 20:36 630K 
 In-Vivo-Assessment-o..>2016-10-04 20:42 691K 
 Correlations-between..>2016-10-04 20:46 697K 
 Association-of-Multi..>2016-10-04 20:49 703K 
 Identification-of-Mo..>2016-10-04 20:43 707K 
 Management-of-Acute-..>2016-10-04 20:42 772K 
 Ancthe-Importance-of..>2016-10-04 20:48 777K 
 A1-Prevention-and-Tr..>2016-10-01 11:18 829K 
 MSD-Clinical-Case.pdf 2016-10-01 11:37 893K 
 Clonal-evolution-in-..>2016-10-01 11:37 1.0M 
 E5-The-Myth-of-Sisyp..>2016-10-01 12:46 1.1M 
 Myelodisplastic-Synd..>2016-10-01 11:36 1.1M 
 Systemic-Mastocytosi..>2016-10-04 20:39 1.1M 
 C3-Diversity-for-the..>2016-10-01 12:01 1.1M 
 P19-Immunosupresive-..>2016-10-01 13:04 1.1M 
 T2-Matched-Unrelated..>2016-10-01 09:40 1.2M 
 E6-Multiple-Myeloma-..>2016-10-01 12:46 1.2M 
 P17-JAK2v617F-Mutati..>2016-10-01 10:06 1.2M 
 C2-Autologus-Transpl..>2016-10-01 12:37 1.3M 
 C17-Death-Causes-in-..>2016-10-01 11:01 1.3M 
 C6-Development-in-Ce..>2016-10-01 12:36 1.3M 
 C14-Acquired-B-Antig..>2016-10-01 11:01 1.3M 
 P10-Aspects-Regardin..>2016-10-01 10:02 1.4M 
 C2-The-Importance-an..>2016-10-01 11:00 1.4M 
 E3-Key-Elements-in-T..>2016-10-03 14:36 1.4M 
 P16-The-Influence-of..>2016-10-01 13:04 1.4M 
 T7-The-National-Prog..>2016-10-01 09:41 1.4M 
 P27-Treatment-with-H..>2016-10-01 10:07 1.5M 
 C6-Blood-Donation-an..>2016-10-01 10:59 1.5M 
 Myelodysplastic-Synd..>2016-10-01 11:37 1.5M 
 E5-Infectious-Risk-M..>2016-10-03 14:36 1.5M 
 P9-Etiopathogeny-of-..>2016-10-01 10:02 1.5M 
 C19-Platelet-Count-V..>2016-10-03 14:24 1.5M 
 P8-Evaluation-of-Aci..>2016-10-01 10:02 1.5M 
 C12-Transfusion-Comp..>2016-10-03 14:24 1.5M 
 C13-Steps-in-Compati..>2016-10-03 14:24 1.5M 
 C12-Relevance-Determ..>2016-10-01 11:01 1.6M 
 P15-Management-of-Pa..>2016-10-01 13:04 1.6M 
 E5-Internal-Quality-..>2016-10-01 10:49 1.6M 
 From-Dissemination-P..>2016-10-04 20:44 1.6M 
 C15-The-Importance-o..>2016-10-01 11:01 1.6M 
 E7-The-Transfuzional..>2016-10-01 10:49 1.6M 
 P1-Primary-Plasma-Ce..>2016-10-01 13:03 1.6M 
 C9-Comparative-Study..>2016-10-03 14:17 1.6M 
 P8-Progressive-Multi..>2016-10-01 13:03 1.6M 
 The-Productivity-of-..>2016-10-01 09:23 1.7M 
 P17-The-Clinic-Agres..>2016-10-01 13:04 1.7M 
 C5-Innovative-method..>2016-10-01 12:01 1.7M 
 C18-Diagnosis-of-Her..>2016-10-01 11:01 1.7M 
 P25-A-Case-Report-of..>2016-10-01 10:06 1.7M 
 P12-Autoimmune-Hemol..>2016-10-01 10:05 1.7M 
 C5-The-Value-of-the-..>2016-10-03 14:17 1.7M 
 P4-The-Importance-of..>2016-10-01 10:02 1.7M 
 C5-Security-and-Crea..>2016-10-01 10:59 1.7M 
 P31-An-unusual-Initi..>2016-10-01 10:07 1.7M 
 C10-Study-on-Frequen..>2016-10-01 11:00 1.8M 
 C16-Pulmonary-Hipert..>2016-10-03 14:23 1.8M 
 C7-Rapid-Determinati..>2016-10-01 10:59 1.8M 
 P14-Indolent-Lymphom..>2016-10-01 13:04 1.8M 
 C6-Detection-of-Mali..>2016-10-01 09:54 1.8M 
 Quercetin-Menadione-..>2016-10-01 11:24 1.8M 
 C13-Prospective-Stud..>2016-10-01 11:01 1.8M 
 C9-Refractory-Anemia..>2016-10-01 09:53 1.8M 
 Beacopp-is-a-Powerfu..>2016-10-01 12:37 1.8M 
 P20-Splenectomy-in-C..>2016-10-01 10:05 1.8M 
 C18-The-Use-of-DNA-T..>2016-10-03 14:23 1.9M 
 P13-Management-of-Ch..>2016-10-01 13:04 1.9M 
 P10-Management-of-Ac..>2016-10-01 13:03 1.9M 
 C4-Quality-Control-o..>2016-10-01 10:59 1.9M 
 P3-Evolution-Immunos..>2016-10-01 10:02 1.9M 
 Non-Hodgkin-Lymphoma..>2016-10-04 20:41 1.9M 
 C15-Minimal-Residual..>2016-10-01 12:07 1.9M 
 E3-External-Audit-Ex..>2016-10-01 10:49 1.9M 
 C3-The-Role-of-Flowc..>2016-10-01 12:36 1.9M 
 C19-Particular-Aspec..>2016-10-01 11:01 1.9M 
 C8-An-Inherited-Rare..>2016-10-03 14:17 1.9M 
 P1-Comparative-Study..>2016-10-01 12:26 1.9M 
 C1-Availability-and-..>2016-10-03 14:17 1.9M 
 C14-Transfusion-Regi..>2016-10-03 14:24 1.9M 
 T4-Donor-Lymphocyte-..>2016-10-01 09:40 1.9M 
 P14-Prognostic-Facto..>2016-10-01 10:06 2.0M 
 E4-External-Quality-..>2016-10-03 14:36 2.0M 
 P9-Musculocutaneous-..>2016-10-01 13:03 2.0M 
 C10-Immunological-St..>2016-10-03 14:17 2.0M 
 A3-European-Guidelin..>2016-10-03 14:08 2.0M 
 P5-Management-of-Inf..>2016-10-01 13:03 2.0M 
 The-Added-Value-of-T..>2016-10-01 12:56 2.0M 
 Myelodysplastic-Synd..>2016-10-01 11:37 2.0M 
 P24-Cost-Benefit-Stu..>2016-10-01 10:06 2.0M 
 E8-The-Information-L..>2016-10-03 14:36 2.0M 
 P7-Primary-Cutaneous..>2016-10-01 13:03 2.0M 
 P4-Treatment-with-Bo..>2016-10-01 13:04 2.0M 
 P5-Invasive-Fungal-I..>2016-10-01 10:02 2.0M 
 P2-Evolution-and-Com..>2016-10-01 13:03 2.0M 
 P18-Evaluation-of-Tr..>2016-10-01 10:06 2.1M 
 E1-Causal-Relationsh..>2016-10-03 14:36 2.1M 
 E2-European-Guidelin..>2016-10-01 10:49 2.1M 
 E2.-Goals-of-Therapy..>2016-10-01 09:31 2.1M 
 C2-Current-Policy-an..>2016-10-03 14:17 2.1M 
 E6-Legislative-Bench..>2016-10-01 10:49 2.1M 
 P30-Rare-Extranodal-..>2016-10-01 10:07 2.1M 
 E9-The-Porphyrias.pdf 2016-10-01 09:31 2.1M 
 E10-The-Classic-BCR-..>2016-10-01 09:31 2.1M 
 A4-Hemophilia-Manage..>2016-10-03 14:08 2.1M 
 P12-Relapsed-and-Ref..>2016-10-01 13:04 2.2M 
 C11-Clinical-Cases-o..>2016-10-03 14:24 2.2M 
 P6-Evolution-of-CLL-..>2016-10-01 13:03 2.2M 
 C4-The-Role-of-Throm..>2016-10-01 09:54 2.2M 
 C9-The-Importance-of..>2016-10-01 10:59 2.2M 
 E5-B-Cell-Receptor-S..>2016-10-01 09:30 2.2M 
 C3-Determination-of-..>2016-10-01 11:00 2.2M 
 P18-Therapeutic-Resu..>2016-10-01 10:05 2.2M 
 E6-Challenges-to-Man..>2016-10-03 14:36 2.3M 
 Atypical-Hemolytic-U..>2016-10-01 11:37 2.3M 
 A2-Hemophilia-Practi..>2016-10-03 14:09 2.3M 
 P3-The-Importance-of..>2016-10-01 13:04 2.3M 
 T1-Late-Complication..>2016-10-01 09:40 2.3M 
 C8-The-Relationship-..>2016-10-01 09:53 2.4M 
 P7-Sustained-Regress..>2016-10-01 10:02 2.4M 
 P2-Differential-Diag..>2016-10-01 10:02 2.4M 
 P3-The-Role-of-Immun..>2016-10-01 12:26 2.4M 
 E7-Management-of-Her..>2016-10-01 12:46 2.4M 
 C11-HLA-Testing-For-..>2016-10-01 11:01 2.4M 
 P11-Thrombotic-and-H..>2016-10-01 13:04 2.4M 
 C2-Prognostic-Factor..>2016-10-01 09:53 2.4M 
 C1-Blood-Donors-Clin..>2016-10-01 11:00 2.4M 
 E12-Paroxysmal-Noctu..>2016-10-01 12:47 2.4M 
 E7-Incidents-Possibl..>2016-10-03 14:36 2.4M 
 E11-Langerhans-Cell-..>2016-10-01 12:46 2.4M 
 Viral-Hepatitis-Sero..>2016-10-01 09:25 2.5M 
 E7-Molecular-Prognos..>2016-10-01 09:30 2.5M 
 E4-Monitoring-and-Co..>2016-10-01 10:49 2.5M 
 C20-Fatal-Cold-Agglu..>2016-10-01 11:01 2.5M 
 C3-Bendamustine-Base..>2016-10-01 09:53 2.5M 
 P20-The-Experience-o..>2016-10-01 13:04 2.5M 
 P23-First-Line-Treat..>2016-10-01 10:06 2.6M 
 Very-Severe-Aplastic..>2016-10-01 09:25 2.6M 
 C17-Anaemic-Syndrome..>2016-10-03 14:23 2.6M 
 P21-Retrospective-St..>2016-10-01 10:06 2.6M 
 C10-Bloodstream-Infe..>2016-10-01 09:53 2.6M 
 C4-Miliary-Tuberculo..>2016-10-01 12:36 2.6M 
 Closed-Collaboration..>2016-10-01 12:36 2.6M 
 P6-Histone-Acetylati..>2016-10-01 12:26 2.6M 
 P22-Vidaza-Therapy-i..>2016-10-01 10:06 2.6M 
 C15-Role-of-Centrifu..>2016-10-03 14:24 2.6M 
 Sarcoidosis-in-patie..>2016-10-01 11:37 2.6M 
 P18-Chronic-Myeloid-..>2016-10-01 13:04 2.6M 
 P21-Myelodysplastic-..>2016-10-01 13:05 2.7M 
 C9-Flow-cytometry-In..>2016-10-01 12:01 2.7M 
 Prognostic-Factors-i..>2016-10-01 12:57 2.7M 
 E2-CLL-Patient-Profi..>2016-10-01 12:45 2.7M 
 C16-The-Role-of-The-..>2016-10-01 11:01 2.7M 
 T3-CMV-Monitoring-af..>2016-10-01 09:40 2.7M 
 T5-Aplastic-Anemia-i..>2016-10-01 09:41 2.8M 
 P6-Megaloblastic-Ane..>2016-10-01 10:02 2.8M 
 P24-Molecular-DIagno..>2016-10-01 13:05 2.8M 
 P1-Case-Presentation..>2016-10-01 10:02 2.8M 
 P28-Acute-Basophilic..>2016-10-01 10:07 2.9M 
 The-Influence-of-Rep..>2016-10-01 09:22 2.9M 
 E2-Risc-Management-i..>2016-10-03 14:36 2.9M 
 P29-Diagnostic-Diffi..>2016-10-01 10:07 2.9M 
 T6-DHAP-vs-IGEV-as-M..>2016-10-01 09:41 2.9M 
 A10-Medical-Staff-an..>2016-10-03 14:09 3.0M 
 Acute-Myeloid-Leukem..>2016-10-01 11:24 3.0M 
 C7-The-Importance-of..>2016-10-03 14:17 3.0M 
 C8-Preliminary-Resul..>2016-10-01 10:59 3.0M 
 E4-Recent-Advances-i..>2016-10-01 12:46 3.0M 
 C7-Next-Generation-S..>2016-10-01 09:54 3.0M 
 C5-Seeking-a-Second-..>2016-10-01 12:36 3.1M 
 Systemic-Light-Chain..>2016-10-01 12:56 3.1M 
 E4-Adult-T-Cell-Leuk..>2016-10-01 09:31 3.1M 
 C1-CALR-and-JAK2-V61..>2016-10-01 12:37 3.1M 
 Human-Babesiosis-in-..>2016-10-01 11:37 3.1M 
 Philadelphia-negativ..>2016-10-01 11:47 3.1M 
 C6-The-Importance-of..>2016-10-03 14:17 3.1M 
 Revista Vol. XXXIV,..>2016-10-20 10:21 3.2M 
 P25-Health-Technolog..>2016-10-01 13:05 3.2M 
 Eltrombopag-treatmen..>2016-10-01 11:24 3.3M 
 P15-Diffuse-Non-Hodg..>2016-10-01 10:06 3.3M 
 P13-Prognostic-Value..>2016-10-01 10:06 3.4M 
 P23-Allotransplantat..>2016-10-01 13:05 3.4M 
 E9-Maintaining-Quali..>2016-10-03 14:36 3.5M 
 C13-Correlations-of-..>2016-10-01 12:07 3.5M 
 C3-Assessment-of-HIV..>2016-10-03 14:17 3.5M 
 P22-The-Frequency-an..>2016-10-01 13:05 3.5M 
 Trends-In-Residual-R..>2016-10-01 09:25 3.6M 
 E10-Mantle-Cell-Lymp..>2016-10-01 12:46 3.6M 
 P5-The-Role-of-Pseud..>2016-10-01 12:26 3.7M 
 C8-Using-FACS-for-Ne..>2016-10-01 12:01 3.7M 
 T8-The-Role-of-Antit..>2016-10-01 09:41 3.7M 
 P26-Regression-of-Ca..>2016-10-01 10:07 3.8M 
 E8-Refractory-Relaps..>2016-10-01 09:31 3.8M 
 Younger-Patients-wit..>2016-10-01 12:57 3.9M 
 P4-Sperm-Chromatin-S..>2016-10-01 12:26 3.9M 
 C4-Atypical-Results-..>2016-10-03 14:17 4.0M 
 E6-Management-of-Acu..>2016-10-01 09:30 4.0M 
 E13-Treatment-Option..>2016-10-01 12:45 4.1M 
 P7-Assessment-of-Per..>2016-10-01 12:26 4.1M 
 P16-The-Clinical-Cou..>2016-10-01 10:06 4.2M 
 C1-Preliminary-Resul..>2016-10-01 09:53 4.3M 
 C7-Signaling-Pathway..>2016-10-01 12:01 4.4M 
 C14-Acute-Leukemia-w..>2016-10-01 12:07 4.4M 
 P2-Dendritic-Cells-A..>2016-10-01 12:26 4.4M 
 Myelodysplastic-synd..>2016-10-01 11:24 4.5M 
 C5-Impact-of-Molecul..>2016-10-01 09:54 4.7M 
 C16-Flow-Cytometry-S..>2016-10-01 12:07 4.7M 
 C19-Flow-Cytometry-A..>2016-10-01 12:06 4.9M 
 Diagnosis-and-Treatm..>2016-10-01 11:47 5.0M 
 T9-Impairment-of-Lip..>2016-10-01 09:41 5.2M 
 E1-Discordant-Compos..>2016-10-01 09:31 5.3M 
 C20-Evaluation-by-Mi..>2016-10-01 12:06 5.6M 
 C10-Characterisation..>2016-10-01 12:01 5.6M 
 C18-Importance-of-Fl..>2016-10-01 12:07 6.7M 
 A-physiopathological..>2016-10-01 11:24 7.8M 
 E3.-Prognostic-Facto..>2016-10-01 09:31 8.5M 
 Consensus-on-minimal..>2016-10-01 11:24 8.8M 
 C12-Adhesion-related..>2016-10-01 12:07 9.1M 
 C2-Evaluation-of-the..>2016-10-01 12:01 10M 
 C2-Evaluation-of-the..>2016-10-01 12:00 10M 
 E14-Actualities-Conc..>2016-10-01 12:45 11M 
 E8-Diffuse-Large-B-C..>2016-10-01 12:46 11M 
 E9-Fanconi-Anemia-Di..>2016-10-01 12:46 11M 
 C11-EuroFlow-Panels-..>2016-10-01 12:01 11M 
 Revista vol. XXXV, N..>2016-10-20 10:22 13M 
 E3-Late-Complication..>2016-10-01 12:46 13M 
 E1-Chronic-Myelomocy..>2016-10-01 12:45 20M 
 Supliment Vol.XXXV, ..>2016-10-20 10:22 39M 
 Caiet de rezumate 20..>2016-10-20 10:20 45M